Healthcare Market Research That Survives the Formulary Committee
Most pharma launches fail at the payer desk, not in the lab. SIS International runs primary research with prescribers, hospital procurement teams, and patient populations across 135+ countries so commercial teams build evidence that clears real reimbursement gates.
Six Research Lanes for Life Sciences Teams
Payer Value Dossier Research
HTA bodies like NICE, G-BA, and HAS require pharmacoeconomic evidence specific to their jurisdiction. We interview payer decision-makers and former formulary committee members to test value stories before submission, so market access teams know which endpoints and comparators actually drive coverage decisions in each market.
KOL Mapping and Physician Panels
Recruiting Key Opinion Leaders is not a database exercise. SIS identifies prescribers by referral network influence and publication weight, then conducts structured expert interviews to capture prescribing rationale, unmet therapeutic need, and switching triggers. We maintain active physician panels across oncology, immunology, rare disease, and CNS.
Patient Journey and Adherence Research
Clinical trial compliance rates misrepresent real-world adherence. We run longitudinal patient journey mapping studies that track where patients drop off: missed refills, caregiver burden, portal fatigue, insurance step-therapy barriers. The output is an evidence-based adherence model tied to behavioral data, not self-reported surveys.
Medical Device Human Factors Validation
The FDA’s HFE guidance and EU MDR usability requirements demand third-party validation before submission. We design and execute formative and summative usability studies for surgical instruments, infusion systems, diagnostic devices, and connected wearables. Intuitive Surgical and Medtronic both demonstrated that late-stage usability failures cost 12-18 months.
Biosimilar Competitive Intelligence
The biosimilar market hinges on formulary positioning, not molecular equivalence. We track competitive launch sequencing, indication prioritization decisions, and payer switching policies across the US, EU5, and Japan. For every reference biologic, we map the full competitive set: pipeline stage, pricing strategy, and contracting approach.
Real-World Evidence Generation
Regulators and payers increasingly require real-world evidence alongside trial data. SIS designs observational studies, claims data analyses, and patient registry research that supplement clinical endpoints with evidence from actual treatment settings. The gap between regulatory approval and reimbursement approval is where most commercial strategies fail.
What SIS Delivers to Life Sciences Commercial Teams
We interview 15-20 formulary directors, former HTA committee members, and payer decision-makers per market. The output is a gap analysis mapping your current evidence package against the specific pharmacoeconomic and clinical endpoints each jurisdiction requires for positive coverage.
Formative and summative human factors research with clinical end-users in their procedural environments. Surgeons, nurses, and technicians test devices under actual operating conditions. Findings are structured for FDA and notified body submission packages.
Multi-week behavioral studies that track where patients drop off therapy: step-therapy insurance barriers, caregiver logistics, portal fatigue, PBM-driven substitutions. Recruited through clinical sites, specialty pharmacies, and patient advocacy networks. Longitudinal data, not single-visit self-reports.
We map Key Opinion Leader influence through referral network analysis and clinical practice pattern research, not publication counts. Structured expert interviews capture which data changes prescribing, which peer recommendations carry weight, and which treatment guidelines physicians actually follow in oncology, immunology, CNS, and rare disease.
THE SIS DIFFERENCE
我們的服務包括：
Recommended
護理人員醫療保健市場研究
ZH_HK 
EN 
AR 
ZH 
NL 
FR 
DE 
IT 
JA 
KO 
PL 
PT 
ES